An Open-label, Phase 3, Multicenter Study to Evaluate the Pharmacokinetics Following a Single Oral Dose of TAK-536 in Pediatric Patients 6 to Less Than 16 Years of Age With Hypertension

Trial Profile

An Open-label, Phase 3, Multicenter Study to Evaluate the Pharmacokinetics Following a Single Oral Dose of TAK-536 in Pediatric Patients 6 to Less Than 16 Years of Age With Hypertension

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Aug 2016

At a glance

  • Drugs Azilsartan (Primary)
  • Indications Hypertension
  • Focus Adverse reactions; Pharmacokinetics; Registrational
  • Sponsors Takeda
  • Most Recent Events

    • 07 Jan 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 19 Oct 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 09 Jul 2015 Planned initiation date changed from 1 Jun 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top